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Chronic exposure of pancreatic islets to sulfony-
lureas (SUs) is known to impair the ability of islets
to respond to subsequent acute stimulation by
SUs or glucose. Nateglinide (NAT) is a novel
insulinotropic agent with a primarily site of action
at /3-cell KATP channels, which is common to the
structurally diverse drugs like repaglinide (REP)
and the SUs. Earlier studies on the kinetics, glucose-
dependence and sensitivity to metabolic inhibitors
of the interaction between NAT and KATP channels
suggested a distinct signaling pathways with NAT
compared to REP, glyburide (GLY) or glimepiride
(GLI). To obtain further evidence for this concept,
the present study compared the insulin secretion in
vitro from rat islets stimulated acutely by NAT, GLY,
GLI or REP at equipotent concentrations during 1-hr
static incubation following overnight treatment
with GLY or tolbutamide (TOL). The islets fully
retained the responsiveness to NAT stimulation
after prolonged pretreatment with both SUs, while
their acute response to REP, GLY, and GLI was
markedly attenuated, confirming the desensitization
of islets. The insulinotropic efficacy of NAT in islets
desensitized to SUs may result from a distinct
receptor/effector mechanism, which contributes to
the unique pharmacological profile of NAT.
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INTRODUCTION
Sulfonylureas (SUs) are widely used in the
treatment of non-insulin-dependent (Type 2)
diabetes. They stimulate insulin secretion by
closing ]-cell plasma membrane KATp chan-
nels, [1] which are formed by the molecular
interaction between a high-affinity SU receptor,
SUR1, and an inwardly rectifying K + channel
subunit, Kir6.2. [2] The closure of KATP channels
leads to the opening of voltage-dependent Ca2 +
channels, Ca2 + influx and stimulation of Ca2 +-
dependent exocytosis.[3] While SUs exert
hypoglycemic action via a direct stimulation of
insulin release during short term administration
in type 2 diabetic patients, their activity declines
during long term applica-tion, which has been
suggested to be directly attributable to a
desensitization of /-cells to SUs. [4-7] In vitro
chronic exposure of pancreatic islets to SUs is
also known to cause impairment of secretory
response to subsequent stimulation by glucose
or SUs. [8-11] The mechanisms underlying
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]B-cell refractoriness after prolonged exposure to
SUs remain at present unclear.
Nateglinide (NAT), a novel D-phenylalanine
derivative, shares the mechanism of action with
SUs to act on KATP channels in pancreatic ]B-cells.
This drug, compared to other marketed KATP
channel-blocking hypoglycemic agents, has
demonstrated unique characteristics including a
rapid onset, short duration of action, sensitivity to
ambient glucose, and resistance to metabolic inhi-
bition, suggesting some aspects of the signaling
pathway(s) mediating NAT’s action are novel and
distinct from those mediating the effects of SUs
and REP. This study was designed to evaluate the
ability of NAT and the com-parators, glyburide
(GLY), glimepiride (GLI), and repaglinide (REP)
to stimulate insulin secretion from isolated rat
islets undergoing prolonged pre-exposure to SUs,
GLY or tolbutamide (TOL). Using static incuba-
tion method, normal rat islets were incubated
overnight (---18hours) in the absence and pre-
sence of therapeutically relevant concentrations
of GLY or TOL before their acute responsiveness
to NAT, GLY, REP, and GLI was determined.
Our results showed that lasting treatment of GLY
or TOL markedly attenuated the islets’ acute
response to GLY, GLI and REP, while NAT
retained ability to stimulate insulin secretion from
SU-desensitized islets. These findings are sugges-
tive of common signaling pathways for the action
of SUs and REP. On the other hand, the effective-
ness of NAT in SU-desensitized islets could imply
the involvement of an action site and/or a recep-
tor/ effector pathway different from those of SUs
and REP. The unique "desensitization-resistant"
properties of NAT may explain some of the phar-
macological differences between those of NAT
and those of SUs and REP. [12,13]
MATERIALS AND METHODS
Islet Isolation
Pancreas were dissected from normal fed male
Sprague Dawley rats (250-275g), which were
euthanized with Na pentobarbital i.p. at
120mg/kg. Islets of Langerhans were isolated by
librase digestion (0.5mg/ml, Boehringer
Mannheim, Germany) followed by a Ficoll
gradient centrifugation. [14]
Static Incubation of Islets Desensitized
to SUs
Freshly isolated islets were handpicked under
a stereomicroscope by gentle suction through a
large firepolished pipette (--4001xm diameter)
into 6015 mm Petri dishes (Corning) contain-
ing 25ml of DMEM (Dulbecco’s Modified
Eagle Medium, Gibco BRL) supplemented with
10% fetal calf serum, 5mM glucose (G5-
DMEM) and 1% BSA (BSA was present in all
incubation media throughout the exper-
iments). Islets were preincubated in a
humidified atmosphere of 95% 02 and 5% CO2
at 37C for I hour.
The islets, after 1 hour preincubation, were
selected in batches of two and placed into
borosilicate glass tubes (1275mm) contain-
ing 500txl G8-DMEM in the presence or
absence of 100nM or 10txM GLY or 100txM
TOL, and incubated over night (--18hours) in a
humidified atmosphere of 95% 02/5% CO2
at 37C. Acute experiments were performed
the following morning to determine the ability
of islets to respond to NAT and other
insulinotropic agents. 500txl 2x treatment of
the concentrations of test hypoglycemic drugs
was added to the tubes (to form 1 ml final
volume) containing either GLY/TOL-treated or
GLY/TOL-untreated islets. The concentrations
of test hypoglycemic drugs were so chosen that
they were comparably effective in control, i.e.,
5txM NAT, 100nM GLY, 100nM GLI and 50nM
REP. All test drugs were first dissolved in
DMSO to form a stock solution of 10 or 30mM
and stored at 4C. The stock solutions were
further diluted with incubation media to the
desired concentrations before each experiment.
Eight independent samples were run for each
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FIGURE 1 Chemical structure of test antidiabetic drugs.
experimental condition. Tubes were incubated
at 37C with intermittent hand shaking for
1hour. At the end of incubation, islet media
(5001/ tube) were transferred to 96 deep-well
plates and stored at -20C for subsequent
insulin analysis.
Insulin Scintillation Proximity Assay (SPA)
The incubation media were diluted by factors
ranging from lx to 20x depending on the
concen-trations of glucose/drugs. The diluted
super-natant was assayed for insulin content
with SPA. [15] The assay employed commercially
available products including a guinea pig
antirat insulin specific antibody (Linco Research
Inc) and scin-tillation proximity Type I reagent
coupled to protein A (Amersham Life Science),
and was performed as a single step assay. All
samples were assayed in duplicate. The
preparation of 96 well sample plates was made
by sequentially adding standard/test samples,
anti-insulin serum, [125I]-insulin tracer, and SPA
reagent, and the final volume equaled 1751/
well. The plates were incubated and vortexed
on a titer plate shaker for approximately 16
hours at room temperature. The plates were
then placed into a Wallac Microbeta 1450 Liquid
Scintillation Counter to be read under a
normalization protocol. The output was in
counts per minute (CPM).
Data Analysis
The sample insulin concentration was calculat-
ed by utilizing a template set up in Excel
spreadsheet that possesses statistical analysis
function. The calculated concentration was
adjusted eventually to reflect the degree of
dilution. The intra- and inter-assay coeffi’cients
of variation were generally between 5% and 8%.
To allow comparison of the hypoglycemic drug-
induced insulin secretion from overnight SU-
treated and untreated islets, data were expressed
as percent of the appropriate con-trois. That is to
say, insulin secretion stimulat-ed by secreta-
gogues in SU-treated and untreated groups was
normalized, respectively, with the amount of
insulin without secreta-gogues in SU-treated
and untreated groups. This transformation cor-
rected for the increase of control values elicited
by overnight treat-ment of SUs. All values were
expressed as the mean _SEM. Statistical signifi-
cance was determined with t-test (single-tailed).
P < 0.05 was considered significantly different.
RESULTS
Drug-induced Insulin Secretion from Islets
with Overnight Treatment of 100nM GLY
It was assumed that prolonged treatment with
SUs would impair islet responsiveness to
physiological and pharmacological stimuli. The
effectiveness of four hypoglycemic agents, NAT,
GLY, GLI, and REP, to stimulate insulin release
from islets cultured overnight (18 hours) in the
presence of 100nM GLY was evaluated and was
compared to that from overnight cultured islets
without GLY to determine the magnitude of
desensitization induced by GLY. In the acute
experiments following overnight incubation, the
concentrations of test drugs were so chosen that
they were comparably effective in stimulating
insulin release at glucose concentration of 8mM,
i.e., NAT at 5M, GLY at 100nM, GLI at 100nM,
and REP at 50nM. These hypoglycemic agents
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stimulated insulin secretion during 1 hour static
incubation from islets cultured overnight without
100nM GLY by a respective 270 44%, 292 42%,
301 26% and 430 +_ 35%. In parallel experiments
on islets cultured overnight with 100nM GLY, the
stimulation factors were, respectively, 354 + 19%,
302 + 13%, 340 + 12%, and 352 + 7%. These data
are illustrated in Figure 2, in which the
stimulation factors of all test agents were not
statistically different between islet groups without
and with pretreatment of 100nM GLY. Thus,
prolonged treatment with glyburide at 100nM did
not appear to render the islets insensitive to
subsequent application of insulin secretagogues.
Drug-induced Insulin Secretion from Islets
with Overnight Treatment of10M GLY
When the concentration of GLY for overnight
treatment was raised by 100-fold to 10zM, the
pattern of the acute response of islets to insulin
secretagogues has changed and the results are
shown in Figure 3. The ability of NAT to
stimulate insulin secretion did not significantly
differ between the GLY untreated control (126
20%) and the GLY pretreated groups (155_
14%). Conversely, the acute stimulation factors
by GLY, REP and GLI in the groups without or
500
[]- 100 nM GLY overnight
100 nM GLY overnight
400
300
200
100
Control
_T_
uM NAT 100 nM GLY 50 nM REP 100 nM GLI
FIGURE 2 Insulin release during I hour static incubation in
response to acute challenges by antidiabetic agents from rat
islets following overnight treatment without (empty bars)
and with (filled bars) 100nM GLY at G8. Data are expressed
as % of appropriate controls GLY, n 16) *p < 0.05 when
compare between data with and without pretreatment.
300
[] 10 uM GLY overnight
10 uM GLY overnight
Control uM NAT 100 nM GLY 50 nM REP 100 nM GLI
FIGURE 3 Insulin release during hour static incubation in
response to acute challenge by antidiabetic agents from rat
islets following overnight treatment without (empty bars)
and with (filled bars) 10M GLY at G8. Data were pooled
from 16 independent samples/condition and expressed as %
of appropriate controls (+GLY). *p < 0.05 when compare
between data with and without pretreatment. Basal insulin
secretion without and with GLY pretreatment was,
respectively, 265 25 and 413 62 U/islet/lh.
with 10M GLY pretreatment were, respectively,
173 + 21% or 112 + 15% (NS) with GLY, 191
18% or 112 + 11% (p < 0.05) with REP, 251 33%
or 138 + 17% (p<0.05) with GLI. Thus, the
ability of GLY, REP and GLI to stimulate insulin
secretion was attenuated following lasting
treatment of islets with 10pM GLY compared to
that without pretreatment. The data demonstrat-
ed that 10M GLY induced islet desensitization
leading to hypo-responsiveness of islets to the
subsequent application of GLY, REP and GLI.
NAT was the only agent that was able to
maintain its insulinotropic efficacy intact in
desensitized islets.
Drug-induced Insulin Secretion from Islets
with Overnight Treatment of 100mM TOL
To further confirm SU induction of islet
desensitization and the effectiveness of NAT,
tolbutamide (TOL), a classic first generation SU,
was also used as a desensitizing agent for the
assessment of the ability of four hypoglycemic
drugs on secretory response of islets. The
stimulation factors of the test drugs during 1
hour static incubation following overnight
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FIGURE 4 Insulin release during hour static incubation in
response to acute challenge by antidiabetic agents from rat
islets following overnight treatment without (empty bars)
and with (filled bars) 1001xM TOL at G8. Data were pooled
from 16 independent samples/condition and expressed as %
of appropriate controls TOL). *p < 0.05 and **p < 0.005
when compare between data with and without pretreatment.
Basal insulin secretion during static incubation without
and with TOL pretreatment was, respectively, 210 22 and
314 16 xU/islet/lh.
treatment of islets with or without 100txM TOL
are illustrated in Figure 4. NAT was able to
stimulate insulin by 240 23% in control and
160 35 after TOL pretreatment. This change
was not statistically significant. On the other
hand, the stimulation factors in control or TOL-
pretreated islet groups were, respectively,
257+27% or 134+23% with GLY, 298 +27% or
137+ 13% with REP, and 260+38% or 155 +20%
with GLI. The results reinforced the argument
that islets desensitized to SUs retain responsive-
ness to NAT but not GLY, REP and GLI. The
changes of insulin secretion in both GLY and
TOL pretreated groups are summarized in the
Table I.
DISCUSSION
The present study demonstrated that prolonged
exposure of pancreatic islets to SUs, GLY or -TOL,
impaired their ability to secrete insulin in
response to subsequent secretagogue stimulation
a phenomenon known as islet desensitization.
Similar results have been previously reported for
both drugs. [8-10,16] As KATp channel blockade
plays key role in the mechanism of action of SUs
and all test drugs in this study, one possible
mechanism for SU desensitization is that chronic
exposure to SUs would result in lasting binding of
SU to SUR1 and closing of KATP channels, and in
turn, a lasting membrane depolarization. The
constant depolarization would lead the ]3-cells to a
refractory state, in which they respond less
effectively to a further stimulation of closing KATP
channels by test secretagogues. Evidence for this
mechanism of SU desensitization associated with
chronic exposure to GLY has been previously
reported. [111 If this were indeed the case, SU
desensitization is likely to be a temporary and
reversible condition of refractoriness of the ]3-cells
to secretagogue stimulation, since KATP channel
activity would eventually recover upon with-
drawal of SUs.
The key finding in the study was that NAT
was the only drug of four test agents which
maintained its insulinotropic efficacy in islets
desensitized to SUs. Given that islets were still
able to vigorously respond to NAT after 18h
pretreatment of SUs, the exhaustion of a finite
insulin store and/or islet secretory machinery
did not appear to be the underlying defect in
TABLE Insulin secretion during lh static incubation following overnight treatment of SUs (% of control)
51xMNAT 100nM GLY 50nM REP 100nM GLI
-10txM GLY overnight 126 20 173 21 191 18 251 33
+10txM GLY overnight 155 14 112 15 112 11" 138 __+ 17"
-100p,M TOL overnight 240 23 257 27 298 27 260 38
+100xM TOL overnight 160 35 134 23** 137 13"* 155 20*
All data in SU-pretreated and non-pretreated groups are expressed, respectively, as percent of insulin secretion
in appropriate control groups without acute stimulation by secretagogues.
*p < 0.05 and **p < 0.005 on data with SU treatment compared to those without.
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desensitized secretion to GLY, REP and GLI. The
insulinotropic action of REP, GLY and GLI was
desensitized by lasting SU exposure, suggestive
of common site of action for these drugs. On the
other hand, the inability of both TOL and GLY to
affect NAT-induced insulin secretion suggested a
distinct mode of action of NAT. Provided that the
mechanism of desensitization was indeed asso-
ciated to the refractoriness of SUR1/KATP chan-
nels in ]3-cells, a possible explanation for the
effectiveness of NAT vs. ineffectiveness of GLY,
REP and GLI in stimulation of insulin following
prolonged pretreatment of SUs would be the
existence of distinct binding sites on SUR1 for
NAT vs. SUs and REP. It is possible that the site
on SUR1 for SUs has become hypo-responsive to
GLY, GLI and REP due to its desensitization
induced by chronic treatment of GLY or TOL,
while the site on SUR1 for NAT remained fully
available to be activated with or without
pretreatment of SUs. Alternatively, the present
data would be reconciled by proposing a second
mechanism of the insulinotropic action of NAT
that is independent of KATP channels.
Being cautious not to over-interpret the in
vitro findings in the present study, we only
speculate that some aspects of signaling
pathways mediating NAT’s effect are markedly
dissimilar from those involving in the effects of
SUs and REP. Although the present study did
not deal with time-dependent secretory pattern
but cumulative stimulation of insulin secre-
tion from islets during certain period of time,
earlier works by others and us reveale
essential differences of NAT action from those
of GLY, GLI and REP with respect to (1) the
kinetics of the interaction of NAT with SUR1
receptor/KATp channels; [17] (2) the kinetics of
in vitrofin vivo insulinotropic action;[18-22] (3)
the glucose-dependence; [23,24] and (4) the
sensitivity to metabolic inhibitors. [25] These
findings collectively indicated the uniqueness
of NAT action and possibly a distinct receptor/
effector system(s). By virtue of these properties,
NAT is able to ameliorate postprandial hyper-
glycemia by augmenting early insulin release,
while SUs and REP may preferentially decrease
postabsorptive hyperglycemia due to their
slower onset and sustained duration of action.
In conclusion, the maintenance of insulino-
tropic efficacy of NAT in islets desensitized to
SUs adds to the list of properties of this agent
that distinguish it from other SUR ligands,
despite the presumed common basic mechanism
of action of said agents.
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